Bio-Path’s (BPTH) “Buy” Rating Reaffirmed at Roth Capital

Bio-Path (NASDAQ:BPTH – Get Rating)‘s stock had its “buy” rating restated by Roth Capital in a report issued on Friday, PriceTargets.com reports.

Separately, StockNews.com assumed coverage on Bio-Path in a research report on Monday, March 13th. They set a “sell” rating on the stock.

Bio-Path Price Performance

NASDAQ:BPTH opened at $1.56 on Friday. Bio-Path has a 52 week low of $1.27 and a 52 week high of $4.48. The stock has a market capitalization of $12.42 million, a PE ratio of -0.79 and a beta of 1.32. The stock’s 50-day moving average price is $1.86 and its 200-day moving average price is $2.27.

Institutional Investors Weigh In On Bio-Path

Several institutional investors have recently bought and sold shares of BPTH. Virtu Financial LLC acquired a new stake in Bio-Path in the 1st quarter worth about $38,000. Renaissance Technologies LLC acquired a new position in shares of Bio-Path during the 2nd quarter worth approximately $70,000. Mount Yale Investment Advisors LLC acquired a new position in shares of Bio-Path during the 3rd quarter worth approximately $81,000. Finally, Citadel Advisors LLC acquired a new position in shares of Bio-Path during the 3rd quarter worth approximately $35,000. 6.42% of the stock is currently owned by institutional investors and hedge funds.

About Bio-Path

(Get Rating)

Bio-Path Holdings, Inc is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.